Journal
MOUNT SINAI JOURNAL OF MEDICINE
Volume 77, Issue 1, Pages 43-49Publisher
WILEY
DOI: 10.1002/msj.20160
Keywords
Alzheimer's disease; amyloid-beta peptide; dementia; oligomer
Categories
Funding
- NIA [P01 AG10491, P50 AG05138]
- Cure Alzheimer's Fund
- NATIONAL INSTITUTE ON AGING [P01AG010491, P50AG005138] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Alzheimer's disease is the most common form of senile dementia. Although the amyloid-beta peptide was identified in 1984 as the major constituent of the senile plaques that characterize the disease, accumulating evidence indicates that the plaque density does not correspond well to the concurrent disease state. In order to resolve this disconnect, a number of recent Studies have shifted away from the senile plaque and classical fibrillar forms of amyloid toward a less well structured species as the proximate neurotoxic factor underlying cognitive failure in Alzheimer's disease: soluble amyloid-beta peptide oligomer (also known as the amyloid-beta peptide-derived diffusible ligand). Paradoxically, several Studies in the last 2 years have shown that picomolar levels of amyloid-beta peptide have neutral activity or perhaps even an essential role in learning and memory. Here we highlight some of the key observations underlying the growing focus on the amyloid-beta peptide oligomer. Mt Sinai J Med 77:43-49, 2010. (C) 2010 Mount Sinai School of Medicine
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available